Detection of coronary stenosis andmyocardial viability using a singleintravenous bolus injection of BR14  by Fisher, Nicholas G et al.
EXPERIMENTAL STUDIES
Detection of Coronary Stenosis and
Myocardial Viability Using a Single
Intravenous Bolus Injection of BR14
Nicholas G. Fisher, MBBS, Howard Leong-Poi, MD, Tadamichi Sakuma, MD, Se-Joong Rim, MD,
Jian Ping Bin, MD, Sanjiv Kaul, MD, FACC
Charlottesville, Virginia
OBJECTIVES The aim of the study was to determine whether coronary stenosis can be detected and
myocardial viability assessed after myocardial infarction from a single venous bolus injection
of BR14, a new ultrasound contrast agent.
BACKGROUND BR14 is an ultrasound contrast agent that, like 201Tl, demonstrates redistribution. Whether
this principle can be used to determine myocardial viability is not known.
METHODS Non-critical (n  6) or flow-limiting (n  4) stenoses were placed on coronary arteries of 10
open-chest dogs, which then underwent 2 h of coronary occlusion followed by reperfusion
through the stenosis. Hyperemia was induced to create flow mismatch in the dogs with
non-critical stenosis. Hyperemia was not induced in dogs with reduced resting coronary blood
flow. All dogs were given 2 ml of BR14 as a bolus injection and serial images were obtained.
Myocardial blood flow (MBF) was measured using radiolabeled microspheres. At the end of
the experiment, tissue staining was performed to determine infarct size and topography.
RESULTS Initial images demonstrated flow mismatch between the normal bed and that subtended by
the stenosis (during hyperemia in dogs without critical stenosis and during rest in those with
reduced resting MBF). The perfusion defect size correlated well with radiolabeled
microsphere-derived hypoperfused zone (r  0.89). Regions within the hypoperfused zone
that had not undergone necrosis showed redistribution, whereas the necrotic regions showed
a persistent defect, the size of which correlated well with infarct size (r  0.80).
CONCLUSIONS Because of its ability to redistribute, BR14 can define regions of relative hypoperfusion and
also discriminate between infarcted and viable tissue within the hypoperfused zone after a
single venous injection. This property lends itself to assessing myocardial perfusion during
exercise stress. (J Am Coll Cardiol 2002;39:523–9) © 2002 by the American College of
Cardiology
We have recently reported that BR14, a novel third-
generation ultrasound contrast agent, demonstrates myocar-
dial redistribution after a single intravenous bolus injection
(1). This property is based on the initial flow-related
distribution of the agent to myocardial beds with transient
capillary retention of the agent. The washout of the bubbles
is faster from high flow than from low flow regions, which
continue to accumulate microbubbles on repeated passes,
resulting in equalization of acoustic signal from all beds over
time. The kinetics of this agent are therefore very similar to
those of 201Tl (2), although the myocardial effect is much
shorter (minutes instead of hours). Because ultrasound data
acquisition is much more rapid than nuclear data acquisition
using standard gamma cameras, the myocardial kinetics of
BR14 can be accurately captured with ultrasound despite
BR14’s short myocardial effect.
We therefore hypothesized that multiple images acquired
over time following a single bolus injection of BR14 could
be used to detect not only relative hypoperfusion distal to a
stenosis, but also the presence and extent of viable tissue in
the hypoperfused zone. To test this hypothesis, we used an
open-chest canine model of partial to complete infarction
distal to either a non-critical or a flow-limiting coronary
stenosis.
METHODS
Animal preparation. The study was approved by the An-
imal Research Committee at the University of Virginia and
conformed to the American Heart Association Guidelines
for the Use of Animals in Research. Ten adult mongrel dogs
were used for the study. They were anesthetized with
30 mg·kg1 of sodium pentobarbital (Abbott Laboratories,
Chicago, Illinois), intubated and ventilated with room air
with a respiratory pump (model 607, Harvard Apparatus,
Natick, Massachusetts). Anesthesia was maintained during
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the experiment with additional sodium pentobarbital as
required. Catheters were inserted into both femoral arteries
for withdrawal of duplicate reference samples during radio-
labeled microsphere injections, and into both femoral veins
for administration of drugs, fluids and microbubbles.
A left lateral thoracotomy was performed and the heart
was suspended in a pericardial cradle. Catheters were placed
in the aortic root as well as the right and left atria for
pressure measurements. The left atrial catheter was also
used for the injection of radiolabeled microspheres. The
proximal sections of the left anterior descending coronary
artery (LAD) and left circumflex coronary artery (LCx)
were dissected from the surrounding tissue. Ultrasonic flow
probes (series SC, Transonics, Mt. Pleasant, Middlesex,
UK) were placed on both coronary arteries and connected to
a digital flow meter (model T206, Transonics) to monitor
epicardial coronary blood flow (CBF). A custom-designed
screw-occluder was also placed around coronary arteries to
enable the production of coronary stenoses of varying
severities. A 20 g catheter was introduced into a distal side
branch of the coronary artery for the measurement of
coronary pressure distal to the stenosis in order to gauge its
severity.
All catheters were connected to fluid pressure transduc-
ers, which, along with the flow meters, were interfaced with
a multi-channel recorder (model ES 2000, Gould Electron-
ics, Eastlake, Ohio). Mean pressures and epicardial CBF
were measured digitally and the signals were displayed
online using Labtech Notebook (Laboratory Technologies,
Bethesda, Maryland).
Myocardial contrast echocardiography. Power pulse-
inversion imaging was performed with a HDI 5000 system
(Phillips-ATL, Bothell, Washington). The ultrasound
transducer (transmit frequency of 1.6 and receive frequency
of 3.3 MHz) was fixed in position in a saline bath, which
served as an acoustic interface between the transducer and
the heart. Imaging was performed at the left ventricular
(LV) mid-papillary muscle short-axis level caudal to the
occluder. The transmit power, image depth, and color gains
were optimized at the beginning of each experiment and
held constant throughout. The focal plane was placed at the
level of the LV posterior wall. A pulse repetition frequency
of 2,500 Hz and a mechanical index of 0.1 were used. Only
end-systolic images (gated to the T wave on the electrocar-
diogram) were acquired and stored digitally using HDI lab.
This system allows direct measurement of acoustic intensity
(AI) in linear units before log compression and post-
processing.
BR14 (Bracco Diagnostics, Geneva, Switzerland) was
administered as a controlled 2 ml bolus over 30 s using a
power injector (Medrad, Pittsburgh, Pennsylvania). This is
a third-generation ultrasound contrast agent consisting of
perfluorocarbon-containing microbubbles stabilized by a
phospholipid monolayer. The mean diameter of the micro-
bubbles is 2.5 to 3.0 m and their mean concentration is
2–5·108/ml1 (3). Every end-systolic frame was captured for
the first 30 s after the injection. The pulsing interval was
then increased to every 10 cardiac cycles for 1 min and then
every 20 cardiac cycles for the next 10 min in order to
minimize microbubble destruction. After alignment of all
images from a single injection sequence (4), regions of
interest were placed over different portions of the LAD and
LCx beds for measurement of AI, which was then plotted
against time. The resultant curves from normal, infarction
and viable tissue were compared.
Radiolabeled microsphere analysis. Myocardial blood
flow (MBF) was measured using left atrial injections of
2  106–11 m radiolabeled microspheres (Dupont
Medical Products) suspended in 4 ml of 0.9% saline and
0.01% Tween-80. Duplicate arterial reference blood sam-
ples were collected from the femoral arteries. At the end of
the experiment, the post mortem LV short-axis slice corre-
sponding to the myocardial contrast echocardiography
(MCE) image was cut into 16 wedge-shaped pieces, and
each piece was further dived into epi-, mid- and endocardial
portions. The tissue and blood reference samples were
counted in a gamma well scintillation camera with a
multi-channel analyzer (model 1282, LKB Wallace, Wells-
ley, Massachusetts), and corrections were made for activity
spilling from one energy window to another with custom-
designed software.
Myocardial blood flow to each myocardial segment was
calculated from the equation Qm  (Cm·Qr)/Cr where Qm
is blood flow to the myocardial segment (ml/min1), Cm is
tissue counts, Qr is the rate of arterial blood sample
withdrawal (ml/min1), and Cr is arterial reference sample
counts (5). Transmural MBF (ml/min/g) to each of the
16 wedge-shaped pieces was calculated as the quotient of
the summed flows to the individual segments within that
piece and their combined weight. Mean MBF to each
region of interest was then calculated by averaging the
transmural MBF in that region, which was defined as will
be described.
Myocardial blood flow in each segment of the LV was
also represented with a parametric image to display the
magnitude of MBF. This custom-designed program uses
colors ranging from orange-brown (low MBF) to white-
yellow (high MBF). All values are normalized to the highest
MBF within the LV short-axis slice. Myocardial blood
flows between adjacent segments are averaged to allow a
smoother transition of color. The regions depicting low
Abbreviations and Acronyms
AI  acoustic intensity
CBF  coronary blood flow
LAD  left anterior descending coronary artery
LCx  left circumflex coronary artery
LV  left ventricle, left ventricular
MBF  myocardial blood flow
MCE  myocardial contrast echocardiography
TTC  triphenyl tetrazolium chloride
524 Fisher et al. JACC Vol. 39, No. 3, 2002
Myocardial Viability Assessment After Acute Myocardial Infarction With BR14 February 6, 2002:523–9
MBF were tested by planimeter and expressed as a percent-
age of the LV short-axis area.
Infarct size determination. The LV short-axis slice cor-
responding to the MCE image was immersed in a solution
of 1.3% 2,3,5-TTC (Sigma, St. Louis, Missouri) and 0.2 M
So¨rensen’s buffer (KH2PO4 and K2HPO4 in distilled water,
pH 7.4) at 37°C for 20 min followed by fixation in 10%
formalin (6). Digital photographic images of these slices
were transferred to computer and the infarct region was
tested by planimeter and expressed as a percentage of the
LV short-axis area.
Experimental protocol. The purpose of the study was to
determine if MBF mismatch could be determined from
initial images following a single injection of BR14 and
whether late images would provide information on myocar-
dial viability. Accordingly, a non-critical stenosis that did
not affect resting CBF was placed on the LAD (n  4) or
LCx (n  2) in six Group I dogs. In four dogs (Group II),
a critical stenosis that reduced both CBF and regional
function was placed on either the LAD (n  2) or LCx
(n  2). The artery with stenosis was then occluded for 2 to
3 h to produce necrosis of varying degrees within the
myocardium distal to the stenosis. The occlusion was
then reversed, but the stenosis was left unaltered. In this
manner, a model of coronary stenosis and partial infarction
distal to the stenosis was created to mimic a common
clinical setting.
In Group I dogs, maximal coronary hyperemia was
induced with a continuous infusion of 1 g/kg1/min1 of
the selective adenosine A2a receptor agonist 2-cyclohexyl-
methyl-idenehydrazino-adenosine (WRC-0470, Discovery
Therapeutics, Richmond, Virginia) in order to produce
MBF disparity between the stenosed and normal beds.
Because this disparity was already present in the Group II
dogs, hyperemia was not induced in them. Radiolabeled
microspheres were injected, following which a bolus of
BR14 was administered and MCE was performed in order
to obtain early and late images. Immediately after comple-
tion of imaging, the dog was sacrificed and the heart slice
corresponding to the MCE image was stained with TTC,
photographed and processed for radiolabeled microsphere
MBF analysis.
Statistical methods. Data are expressed as mean  1
standard deviation. Differences between hypoperfused and
normal myocardium in the initial images as well as between
viable and infarcted myocardium in the delayed images were
assessed using Student’s paired t test. Correlations were
calculated using least-fit regression analyses. Differences
were considered significant at p  0.05 (two-sided).
RESULTS
Group I dogs. Figure 1 illustrates images from one Group
I dog. During hyperemia, a large zone of hypoperfusion was
noted in the bed supplied by the non-critical stenosis (Fig.
1B) that corresponded to the region with relatively lower
radiolabeled-microsphere derived MBF (Fig. 1B). Within
10 min, however, this hypoperfused zone was significantly
smaller (Fig. 1C) and corresponded to the infarct size on
TTC staining (Fig. 1D). Figure 2 depicts time-versus-AI
plots from different myocardial regions. The non-necrotic
region within the initially hypoperfused zone showed an
Figure 1. Example from a Group I dog. (A) Parametric image obtained from microsphere-derived flow during maximal hyperemia indicating hypoperfusion
in the left circumflex coronary artery (LCx) territory distal to a non-critical stenosis. The myocardial contrast echocardiography (MCE) image taken early
after injection matches this image (B), but the late MCE image (C) matches the infarction (D). In this instance a stenosis was first created and then
infarction produced by total occlusion of the artery at the site of stenosis. Reflow was then established with the stenosis remaining unchanged. See text for
details.
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increase in AI to the level seen in the normal myocardium,
whereas the necrotic area showed no change in AI during
the entire imaging sequence. Similar results were found in
all Group I dogs.
Group II dogs. This group of dogs did not undergo
hyperemia because resting MBF was already reduced be-
cause of a critical stenosis. Figure 3 depicts images from one
Group II dog. A large hypoperfused zone was seen distal to
the stenosis initially after injection of BR14 (Fig. 3B)
corresponding to the zone of reduced resting MBF as
measured by radiolabeled microspheres (Fig. 3A). The
normal bed showed good perfusion consistent with the
Figure 2. Changes in acoustic intensity (AI) values from the left anterior descending (LAD) and left circumflex coronary artery (LCx) beds (denoted on
the images in Fig. 1) following the injection of BR14 during maximal hyperemia. The LCx has a residual non-critical stenosis, whereas the LAD bed is
normal. Although a flow mismatch is seen early after injection, AI in all viable tissue is similar at a later point in time, indicating redistribution. Where
infarction had occurred a persistent perfusion defect remained. See text for details.
Figure 3. Example from a Group II dog that had reduced resting myocardial blood flow (MBF). (A) Parametric image obtained from microsphere
derived-MBF indicating an ischemic LCx territory. The MCE image taken early after injection matches this image (B), but the late MCE image (C)
matches the infarction (D). See text for details. The preparation of this animal was the same as in Figure 1 except that hyperemia was not used. Other
abbreviations as in Figure 1.
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microsphere data. Similar to the Group I dogs, however, the
region within the hypoperfused bed that had not undergone
necrosis showed normalization of AI on late imaging (Fig.
3C). Only the necrotic regions (confirmed on TTC stain-
ing) continued to show persistent hypoperfusion (Fig. 3D).
Figure 4 depicts time-versus-AI plots from different myo-
cardial regions. Again, the necrotic region showed no
change in AI over time, whereas the viable region showed
redistribution. All Group II dogs showed similar results.
Combined results. Figure 5 shows the relation between
the size of the hypoperfused bed on MCE during the initial
imaging period and the radiolabeled-microsphere derived
extent of relative hypoperfusion. As expected, a close rela-
tion was observed. Figure 6 depicts the relation between the
extent of hypoperfused myocardium during late imaging
and the infarct size measured by TTC staining. Once again,
a good correlation is noted between the two. Thus, with a
single injection of BR14, both the region of relative hypo-
perfusion (potentially ischemic in Group I and actually
ischemic in Group II dogs) as well as the infarct size could
be measured during MCE. Regions with relative hypoper-
fusion that had not undergone necrosis demonstrated redis-
tribution. The AI ratios between the hypoperfused and
normal beds within necrotic and viable tissue over time are
Figure 4. Changes in AI values from the LAD and LCx beds (denoted on the images in Figure 3) following the injection of BR14. The LCx has a residual
critical stenosis, whereas the LAD bed is normal. Although a flow mismatch is seen early after injection, AI in all viable tissue is similar at a later point
in time, indicating redistribution. Where infarction had occurred, a persistent perfusion defect remained. See text for details. Abbreviations as in Figure 2.
Figure 5. Correlation between radiolabeled-microsphere derived hypoperfused territory and myocardial contrast echocardiography-derived risk area and in
all 10 dogs. See text for details. LV  left ventricular; MCE  myocardial contrast echocardiography.
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shown in Table 1. These ratios were significantly different
between the infarcted and viable myocardium. In particular,
viable myocardium had the same VI as the normal myocar-
dium at late imaging.
Observer variability. The correlation coefficients between
two sets of observations (n  12) performed by the same
observer (intraobserver) and two sets performed by two
separate observers (interobserver) were 0.97 (SEE  8%)
and 0.96 (SEE  9%) respectively.
DISCUSSION
In this study we have shown that a single injection of BR14
can be used to detect relative hypoperfusion distal to a
stenosis as well as the extent of viable and/or necrotic tissue
within the hypoperfused zone. The discrimination between
necrotic and viable tissue is based on the ability of BR14 to
redistribute to viable regions (1). These characteristics are
very similar to those of 201Tl (2).
Assessment of viability using radioisotopes. When a
defect is seen during peak stress on nuclear imaging using
single-photon tracers, it implies the presence of hypo-
perfusion. Whether this hypoperfusion is fixed (i.e., also
present at rest, in which case it represents necrotic tissue)
or reversible (i.e., no longer present at rest, in which case
it represents viable tissue) can be determined with 99mTc
agents using a second injection at rest (7). Because, unlike
most 99mTc agents (8,9), 201Tl demonstrates redistribution
(2), a second injection is generally not required to discrim-
inate between infarcted and viable myocardium, although
some centers use 201Tl reinjection to improve count statis-
tics.
This approach has been used in nuclear cardiology
because traditionally wall thickening could not be assessed
using myocardial perfusion tracers; only relative myo-
cardial perfusion could be measured. In the case of echo-
cardiography, wall thickening can be easily assessed. In
this regard, the approach is more physiological and clin-
ically relevant because viability is an issue only when
significant regional dysfunction is present at rest. Adequate
myocardial enhancement on MCE at rest in a region with
reduced function implies the presence of viable myocar-
dium.
Assessment of viability by MCE. With most second-
generation contrast agents, viability can be easily assessed by
the presence of normal or near-normal myocardial enhance-
ment in dysfunctional regions with adequate MBF (stunned
myocardium). In dysfunctional regions with reduced MBF
(hibernating myocardium), however, the interval between
microbubble destruction and imaging needs to be prolonged
(10). This approach can be technically challenging in the
clinical setting. Our results indicate that with BR14, delayed
imaging can answer the question without need for prolong-
ing the pulsing interval. This property of BR14 could make
it easier to detect viable myocardium, particularly in low
flow regions such as in our Group II dogs.
Another advantage of echocardiography over nuclear
Figure 6. Correlation between triphenyl tetrazolium chloride-determined infarct and myocardial contrast echocardiography-derived perfusion defect sizes
on late imaging and in all 10 dogs. See text for details. LV left ventricular; MCE myocardial contrast echocardiography; TTC triphenyl tetrazolium
chloride.
Table 1. Acoustic Intensity Ratios in the Hypoperfused Zone







Infarcted 0.13  0.12 0.35  0.19
Viable 0.61  0.11 1.01  0.08
p Value  0.01  0.001
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cardiology is the superior spatial resolution allowing assess-
ment of the transmural distribution of myocardial perfusion.
As seen from Figures 1 and 3, the perfusion defect on late
imaging is similar in topography to the infarct. This
property could assist in determining the effect of infarction
on recovery of resting function as well as LV remodeling
(11). It could thus assist in the proper selection of patients
who should undergo vigorous therapy to prevent or atten-
uate LV remodeling.
The traditional echocardiographic approach for assess-
ment of myocardial viability has been the use of dobutamine
(12,13). Although this technique has been clinically very
useful, it entails time and unpleasant, if not serious, side
effects (14). Our results indicate that a single injection of
BR14 can provide an accurate assessment of myocardial
viability at rest without recourse to drugs. Furthermore, a
direct assessment of the spatial distribution of necrosis may
offer more insights toward individual patient management
than simply the ability of the myocardium to respond to
catecholamines (10,15).
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